Reagent Manufacturing for a Novel CRISPR-Based Diagnostic SARS CoV-2 Test
Mammoth Biosciences is developing a turnkey workstation to run their CRISPR-based SARS-CoV-2 molecular assay on automated liquid handling equipment. Once approved, the diagnostic workflow will reduce the time required for testing while maintaining the gold standard accuracy of polymerase chain reaction.
However, in order to increase both centralized and decentralized testing capacity, the workflow needs to be scaled.
Download this whitepaper to discover how the manufacturing process was successfully scaled using:
- Operational support
- A customized solution
- Highly collaborative and strategic engagement